Stocks Health care PBYI
NASDAQ · Health carePuma Biotechnology, Inc. (PBYI)
Puma Biotechnology, Inc. brought in $231.2M of revenue over the twelve months to June 30, 2026, down 2.9% from a year earlier. Net income was $26.7M, a net margin of 11.6%. Operating cash flow minus capital spending left $41.7M of free cash flow in fiscal 2025. At June 30, 2026 it held $36.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Puma Biotechnology, Inc. does
Puma Biotechnology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBYI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $228.4M | $31.1M | $0.61 | $41.7M |
| 2024 | $230.5M | $30.3M | $0.62 | $38.9M |
| 2023 | $235.6M | $21.6M | $0.45 | $26.9M |
| 2022 | $228M | $2K | $0.00 | -$15.8M |
| 2021 | $253.2M | -$29.1M | -$0.72 | $20.7M |
| 2020 | $225.1M | -$60M | -$1.52 | $727K |
Latest SEC filings
What Puma Biotechnology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 16, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
- April 28, 2026Additional proxy material DEFA14A
- April 28, 2026
- April 28, 2026Proxy statement DEF 14A
- April 7, 2026Preliminary proxy statement PRE 14A
- March 27, 2026Passive stake changed SCHEDULE 13G/A
Questions about PBYI
What does Puma Biotechnology, Inc. do?
Puma Biotechnology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBYI.
Is Puma Biotechnology, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $26.7M on revenue of $231.2M, a net margin of 11.6%.
How much revenue does Puma Biotechnology, Inc. make?
Over the twelve months to June 30, 2026 Puma Biotechnology, Inc. reported revenue of $231.2M. That is 2.9% less than a year earlier.
When did Puma Biotechnology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 16, 2026.
Similar companies
Follow PBYI
Get an email when Puma Biotechnology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PBYI: get an email when it filesWhere the numbers come from
Financial figures are the values Puma Biotechnology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.